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M A J O R A R T I C L E
Gene Expression and Cytokine Proﬁle Correlate
With Mycobacterial Growth in a Human BCG
Challenge Model
Magali Matsumiya,a Iman Satti,a Agnieszka Chomka, Stephanie A. Harris, Lisa Stockdale, Joel Meyer, Helen A. Fletcher,b
and Helen McShane
The Jenner Institute, University of Oxford, United Kingdom
Background. Bacillus Calmette-Guerin (BCG) vaccine is the most widely administered vaccine in the world, yet
its mechanism of action remains unclear. We hypothesize that certain immune pathways are associated with reduced
mycobacterial growth following BCG challenge in human volunteers.
Methods. We used samples from a mycobacterial challenge in which previously BCG-vaccinated or BCG-naive
adults in the United Kingdom were challenged intradermally with a standard dose of BCG. Any remaining BCG was
quantiﬁed in a skin biopsy specimen obtained 2 weeks after challenge and used as a measure of BCG growth and
functional antimycobacterial immunity. We measured the immune response over the 2-week challenge, using DNA
microarrays and ﬂow cytometry, and correlated this with mycobacterial growth.
Results. The magnitude of the immune response to BCG is greater in previously vaccinated volunteers, and this
correlates with reduced mycobacterial growth but increased scarring at the vaccination site. In particular, the inter-
feron γ and interleukin 17 pathways are strongly induced in previously vaccinated volunteers and correlate with re-
duced mycobacterial growth in this population.
Conclusion. This study identiﬁes pathways associated with control of mycobacterial growth in vivo in human
volunteers and supports the use of BCG challenge as a tool for evaluating vaccine efﬁcacy and identifying mecha-
nisms of antimycobacterial immunity.
Keywords. BCG; transcriptomics; cytokines; vaccines; tuberculosis.
Tuberculosis is a major global health problem, with an
estimated 8.6 million cases and 1.3 million deaths in
2012 [1]. Effective vaccination is likely to be necessary
for the long-term control of the tuberculosis epidemic.
However, bacillus Calmette-Guerin (BCG) vaccine, the
only currently licensed vaccine for the prevention of tu-
berculosis, provides variable protection against pulmo-
nary disease [2], and in tuberculosis-endemic countries,
the incidence of tuberculosis remains high despite wide-
spread BCG coverage. Research efforts into new tuber-
culosis vaccines have focused largely on 2 strategies: (1)
modify BCG or replace it with an attenuated strain of
Mycobacterium tuberculosis, or (2) improve on the pro-
tection of BCG through prime-boost regimens, often
using viral vectors expressing M. tuberculosis antigens,
to enhance the memory cells primed by vaccination
with BCG [3]. Twelve novel tuberculosis vaccines are
currently in clinical trials [1]. The results of the ﬁrst ef-
ﬁcacy trial of a novel vaccine, modiﬁed vaccinia virus
expressing antigen 85A (MVA85A), were published in
early 2013 [4] and showed no enhanced protection,
compared with BCG alone, in South African infants.
Despite these advances, the development of new vac-
cines against tuberculosis remains hampered by the
difﬁculty in evaluating efﬁcacy. The frequency of new
M. tuberculosis infection is very low, even in high-burden
settings, making efﬁcacy trials long and expensive. Al-
though animal models exist, none exhibit all stages of
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human disease, and the extent to which they accurately predict
protection in humans is unclear. Because of the tissue damage
caused by tuberculosis and the difﬁculty in ensuring complete
clearance of infection, human challenge with M. tuberculosis is
currently not ethically possible. The clinical trial from which
samples in this study were collected was conducted as part of
an effort to create a human model of mycobacterial growth
and its control, using BCG as a challenge organism. The trial in-
cluded 4 groups who received the following vaccination regimes
before BCG challenge: A, none; B,MVA85A; C, BCG (≥6months
prior to the trial); and D, BCG (≥6 months prior to the trial)
followed by MVA85A 4 weeks before challenge. Groups B and
D, who received MVA85A, were not included in this study, but
the original group names have been retained here. The primary
analysis of the trial showed a reduction in BCG growth in the pre-
viously BCG-vaccinated groups, compared with the BCG-naive
groups, and that BCG growth was inversely correlated to the
interferon γ (IFN-γ) enzyme-linked immunosorbent assay
(ELISPOT) response to puriﬁed protein derivative tuberculin
(PPD-T) [5]. In this study, we used ﬂow cytometry and gene ex-
pression analysis to identify biological correlates of mycobacterial
control in this setting, using stored samples from the trial.
MATERIALS AND METHODS
Study Design
Samples used in this study were obtained from a phase 1 trial
(clinical trials registration: NCT01194180), which was approved
by the Medicines and Healthcare Products Regulatory Agency
(EudraCT 2010-018425-19) and the Oxfordshire Research Eth-
ics Committee A (reference 10/H0505/31). The study design
was described in detail by Harris et al [5].
Groups included in this study are group A (BCG naive) and
group C (BCG vaccinated; median time since vaccination, 10
years). All volunteers were intradermally challenged with a
standard vaccine dose of BCG (SSI, Statens Serum Institut);
0.1 mL containing 2 × 105–8 × 105 colony-forming units [CFU])
as previously described [5]. A single operator performed skin
biopsies on the BCG challenge site of all volunteers 2 weeks
after challenge, as previously described [6]. All biopsy speci-
mens were processed, DNA was extracted, and quantitative po-
lymerase chain reaction (qPCR) was performed as previously
detailed [5] and described below. Peripheral blood mononuclear
cells (PBMCs) for gene expression analysis were collected and
cryopreserved as previously described [7] on the day of chal-
lenge (day 0) and days 2, 7, and 14 after challenge. Whole
blood specimens for cytokine analysis were collected on days
0, 2, and 14 and processed as described below.
BCG Quantiﬁcation by PCR
Biopsy specimens were snap frozen on the day of challenge and
later thawed and homogenized in 1 mL of sterile phosphate-
buffered saline (PBS). Homogenate was thawed, and BCG
DNA from 200 µL of homogenate was released using the
tough microorganism lysing kit (Precellys) in a Precellys 24 ma-
chine by shaking 3 times at 6500 rpm for 30 seconds each. Ho-
mogenate was transferred to a separate tube, and 50 µL of PBS
was used to wash the remaining homogenate from the beads.
Next, 180 µL of animal tissue lysis buffer and 20 µL of protein-
ase K (Qiagen) were added, vortexed, and incubated at 56°C for
4 hours. From this point, the extractions were performed as pre-
viously described [5, 6]. qPCR primers ET 1 and ET 3 were used
for detection of BCG DNA. The sequences used are given in the
article by Harris et al [5]. PCR reactions were performed as
previously described [5, 6], using BCG-naive macaque tissue
homogenate as a negative control. A standard curve was ob-
tained by extracting BCG DNA from 1 in 10 serial dilutions
of 5 pooled vaccine vials in PBS and correcting for live BCG
from the corresponding CFU on solid agar.
Gene Expression Analysis
Cryopreserved PBMCs were rapidly thawed in a 37°C water
bath and transferred to a 15-mL Falcon tube containing 10
mL of R10 (Roswell Park Memorial Institute medium with
10% fetal calf serum, 1% L-glutamine, 1% Pen-Strep, and 1% so-
dium pyruvate). PBMCs were pelleted, and supernatants were
discarded and resuspended in 10 mL of R10 with 20 µL of Ben-
zonase (Merck Chemicals) and rested overnight at 37°C in 5%
CO2. PBMCs were counted on a Casy Counter (Roche), and
2 × 106 cells were stimulated for 12 hours with either R10 me-
dium alone or containing 1 × 106 CFU of BCG (Statens Serum
Institute). After 12 hours, supernatant was removed, and the
PBMCs were resuspended in 350 µL of RLT buffer (Qiagen)
containing 10 µL/mL β-mercaptoethanol and frozen at −20C.
RNA was extracted using the RNeasy kit (Qiagen) according
to manufacturer’s instructions, including the optional protocol
for DNA digestion (RNase-free DNase kit, Qiagen). Messenger
RNAwas ampliﬁed from the total RNA, using the Illumina To-
talprep kit (Ambion) according to manufacturer’s instructions.
RNA quantity and quality was assessed using a Nanodrop ND-
1000 Spectrophotometer and an Agilent Bioanalyzer (Agilent
RNA 6000 Nano Kit). A total of 750 ng of ampliﬁed comple-
mentary RNA was labeled and hybridized to Illumina Human
HT-12 v4 beadchips as speciﬁed in the manufacturer’s instruc-
tions. Beadchips were scanned on an Illumina iScan machine,
and data were extracted using the GenomeStudio software.
Stimulation of Whole Blood
Mycobacteria-speciﬁc intracellular cytokines (ICS) were mea-
sured in whole-blood samples as previously described [8].
Brieﬂy, blood samples were incubated with 1 µg/mL αCD28
and 1 µg/mL αCD49d (BD) and stimulated with 20 µg/mL
PPD (SSI, Denmark) and 5 µg/mL staphylococcal enterotoxin
B (Sigma Aldrich); unstimulated blood samples served as
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Figure 1. Bacillus Calmette-Guerin (BCG) vaccination induces changes in gene expression in unstimulated peripheral blood mononuclear cells (PBMCs). Heat map showing changes in expression of genes
associated with T-cell activation, innate immunity, apoptosis, and glycolysis over the 14-day challenge period in unstimulated PBMCs for the BCG-naive group (A) and the previously BCG-vaccinated group (C).
Median log2 fold changes from day 0 are shown.
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negative controls . Stimulated and unstimulated blood samples
were incubated at 37°C in 5% CO2 for 6 hours, 3 µg/mL
Brefeldin A (Sigma Aldrich) was added, and cells were incubat-
ed for another 6 hours in a timed water bath. Whole-blood
samples were then treated with 2 mM ethylenediaminetetraace-
tic acid (Gibco), and red blood cells were lysed using FACS
Lysing solution (BD). Samples were frozen for batched ICS
analysis.
ICS Analysis
Stimulated and ﬁxed whole-blood samples were permeabilized
and incubated with antibodies against CD3 (AF700), tumor ne-
crosis factor α (TNF-α; peridinin chlorophyll protein–cyanine
5.5 [Cy5.5]) and IFN-γ (phycoerythrin [PE]–Cy7) from
Ebioscience. CD4 (allophycocyanin [APC]), CD14 (Paciﬁc
Blue), and interleukin 17 (IL-17; AF488) from Biolegend. CD8
(APC-H7) was obtained from BD, and interleukin 2 (IL-2; PE)
was obtained from Beckman Coulter. Samples were acquired on
an LSRII (Becton Dickinson). Responses were analyzed using
FlowJo (Tree Star), and cytokines were measured in singlet
CD14−CD3+ cells, CD4+ T cells, or CD8+ T cells and in singlet
CD3−CD14+ cells. The gating strategy is speciﬁed in Supple-
mentary Figure 3. Presented results are percentages of cyto-
kine-expressing cells minus responses in unstimulated cells.
Polyfunctional cytokine immune responses were analyzed
using Spice software (http://exon.niaid.nih.gov/spice/). The
monocyte to lymphocyte ratio was calculated as the ratio of sin-
glet CD14+CD3− cells to singlet CD3+CD14− cells.
Microarray Analysis
Raw Illumina probe data were exported from Beadstudio and
screened for quality, using the R package arrayQualityMetrics
[9]. Gene expression data were analyzed using the bioconductor
platform in R [10]. Genes not expressed above background lev-
els in any sample were removed (P < .05). In limma [11, 12],
background correction and quantile normalization were per-
formed using the neqc function [13]. Probes with an interquar-
tile intensity range of < 0.3 (log2 transformed) across all samples
were ﬁltered using bioconductor’s geneﬁlter package. Lists of
differentially expressed genes were generated using limma
(P value cutoff, .05 after Benjamini-Hochberg correction [11–
13]). Pathway analysis was performed using the Internet-
based tool DAVID (Database for Annotation, Visualisation
and Integrated Discovery) [14]. Heat maps were created in R,
using the gplots package [15].
Genes selected for inclusion in Figure 1 were selected as they
contributed most highly to the enrichment of the gene ontology
categories shown in Table 1. The genes in Table 2 were selected
to include those from each group (A and C) with the highest
fold changes (and equivalent values for the other group, if it
was only highly differentially expressed in one group). A few
additional genes, such as the one encoding TNF, are included
for interest because of their importance to the ﬁeld.
Statistical Analysis
Statistical analysis was performed using Prism (GraphPad) soft-
ware. The Mann–Whitney U test was used to compare cytokine
responses between the 2 study groups. Differences were consid-
ered statistically signiﬁcant at P values of < .05.
Determination of the BCG Scar Severity Rank
Photographs of the BCG injection challenge site were taken
on day 14, immediately before biopsy, to document each partic-
ipant’s reaction to BCG. A high degree of heterogeneity in local
reactions to BCG was noted. The photographs were ranked
Table 1. Gene Ontology Terms AssociatedWith Bacillus Calmette-
Guerin (BCG) Vaccination
Study Group, Gene
Ontology Term
Genes, No.
(%)
P Value
Unadjusted Adjusteda
Group A
Immune response 33 (10.9) 4.50E-08 8.10E-05
Regulation of cytokine
production
14 (4.6) 6.40E-06 5.70E-03
Defense response 26 (8.6) 1.50E-05 9.30E-03
Chemical homeostasis 23 (7.6) 2.20E-05 1.00E-02
Homeostatic process 27 (8.9) 1.50E-04 5.40E-02
Group C
Establishment of protein
localization
84 (7) 8.70E-07 5.70E-04
Cell activation 42 (3.5) 7.40E-07 6.10E-04
Glycolysis 15 (1.3) 7.00E-07 7.60E-04
Leukocyte activation 38 (3.2) 4.80E-07 1.60E-03
Intracellular transport 72 (6) 5.30E-06 2.50E-03
T-cell activation 23 (1.9) 1.20E-05 4.40E-03
Lymphocyte activation 30 (2.5) 2.10E-05 6.20E-03
Hexose catabolic process 16 (1.3) 2.10E-05 6.70E-03
Glucose metabolic process 25 (2.1) 3.20E-05 7.90E-03
Monosaccharide catabolic
process
16 (1.3) 3.00E-05 8.00E-03
Positive regulation of
apoptosis
49 (4.1) 8.30E-05 1.90E-02
Immune system
development
35 (2.9) 1.40E-04 2.40E-02
Induction of apoptosis 39 (3.3) 1.30E-04 2.50E-02
T-cell differentiation 14 (1.2) 1.80E-04 2.50E-02
Hexose metabolic process 27 (2.3) 1.90E-04 2.50E-02
Generation of precursor
metabolites and energy
38 (3.2) 1.70E-04 2.60E-02
Phosphate metabolic
process
90 (7.5) 2.20E-04 2.90E-02
Differentially expressed genes over the 2-week challenge period were
determined using linear modeling in limma. The lists of differentially
expressed genes for each group were analyzed using DAVID to identify
significantly enriched gene ontology terms.
a By the Benjamini–Hochberg method.
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continuously, from least to most severe, by the trial physician
subsequently through the end of the trial but before the quan-
tiﬁcation of BCG in biopsy specimens. The ranking took ac-
count of size, redness, and swelling of the inﬂammatory
reaction at the site of injection and is speciﬁed in Supplemen-
tary Figure 1.
RESULTS
Immune Response to BCG Is Weaker in BCG-Naive Volunteers
BCG induces changes in gene expression of circulating PBMCs
over the 2-week period following BCG challenge. Twenty-four
volunteers, 13 with a prior history of BCG vaccination, were
challenged with BCG, and blood specimens were collected im-
mediately before challenge (day 0) and 2, 7, and 14 days later.
We determined gene expression in unstimulated PBMCs and
identiﬁed genes within the groups at each time point that
were differentially expressed relative to baseline. Both groups
showed changes in expression of genes related to the immune
system during the challenge, but the fold change and the num-
ber of signiﬁcantly differentially expressed genes were higher in
the previously vaccinated group (group C). A total of 1500
genes were differentially expressed, compared with baseline,
over the challenge period in group C, whereas 500 were differ-
entially expressed in group A. In both groups, differentially ex-
pressed genes showed enrichment of genes associated with the
immune response, T-cell activation, glycolysis, and apoptosis,
but these changes were stronger in group C than in group A
(Table 1 and Figure 1). The greatest number of differentially
expressed genes was seen 2 days after challenge, although for
genes involved in T-cell activation the peak occurred later.
For all volunteers, we also determined gene expression pro-
ﬁles of PBMCs stimulated for 12 hours with BCG. As in the
unstimulated samples, differentially expressed genes in both
groups reﬂected a strong innate component in the immune re-
sponse to BCG. However, fold changes were much higher in
group C, showing a role for memory responses in increasing
the magnitude of the immune response to BCG. Fold changes
for BCG-stimulated PBMCs compared with unstimulated
PBMCs, are shown for a subset of genes on days 0 and 14
(the times of BCG challenge and biopsy, respectively) for the
2 groups in Table 2.
Table 2. Changes in Gene Expression Following Bacillus Calmette-Guerin (BCG) Stimulation Are Higher in Group C, Compared With
Group A
Probe Identifier Symbol
Challenge Day 14
Group A Group C Group A Group C
Adjusted P Fold Change Adjusted P Fold Change Adjusted P Fold Change Adjusted P Fold Change
ILMN_1726448 MMP1 9.90E-23 31.86 3.87E-34 145.70 3.36E-19 24.30 4.13E-27 60.08
ILMN_1699651 IL6 5.44E-13 42.12 2.03E-25 138.98 3.10E-13 25.03 2.16E-18 35.90
ILMN_2158713 IL1F9 1.89E-31 99.69 1.57E-47 130.36 7.15E-30 112.53 6.32E-41 63.45
ILMN_1663866 TGFBI 1.05E-31 −71.21 1.32E-43 −128.73 8.92E-31 −89.07 1.84E-41 −120.62
ILMN_2207291 IFNG 3.63E-21 46.31 4.40E-39 127.96 6.78E-24 118.38 6.26E-40 188.75
ILMN_1668063 FCN1 1.55E-26 −74.84 1.30E-46 −127.53 6.71E-25 −81.87 1.10E-41 −81.58
ILMN_1773245 CCL3L1 6.58E-18 39.48 7.79E-33 103.31 9.39E-17 44.33 2.42E-28 28.85
ILMN_1661861 CSF2 2.03E-22 54.93 6.57E-48 100.97 1.20E-21 69.61 1.47E-43 70.41
ILMN_1658483 IL1A 5.26E-11 29.16 2.15E-23 85.06 5.96E-10 16.83 7.75E-17 32.09
ILMN_1657234 CCL20 5.74E-11 18.08 2.87E-24 83.86 1.04E-10 18.74 1.48E-16 31.41
ILMN_2203271 FPR3 2.85E-38 −48.24 1.55E-52 −83.48 9.00E-36 −47.24 9.44E-52 −92.77
ILMN_1774685 IL24 1.82E-11 21.50 9.31E-20 48.26 1.74E-15 10.32 9.82E-16 9.80
ILMN_1686623 CSF1R 4.44E-23 −15.60 1.25E-34 −46.77 1.49E-24 −24.18 9.56E-32 −39.03
ILMN_1797009 F3 2.07E-13 5.70 8.03E-32 36.83 1.35E-14 7.72 3.69E-26 13.33
ILMN_1815205 LYZ 3.87E-22 −20.81 1.84E-29 −34.57 1.46E-20 −21.98 1.19E-24 −22.82
ILMN_1703538 AIF1 2.49E-19 −9.61 1.54E-44 −29.73 4.01E-18 −10.35 1.20E-36 −14.82
ILMN_1671509 CCL3 1.95E-17 22.48 5.86E-32 29.60 6.49E-16 23.22 4.06E-25 16.24
ILMN_1653766 CCL24 2.87E-14 −14.44 3.26E-26 −28.07 2.61E-15 −22.36 4.22E-26 −33.30
ILMN_1735910 VMO1 9.90E-23 −16.89 9.60E-31 −25.46 2.19E-19 −13.95 1.56E-27 −20.95
ILMN_1730816 GPR162 3.87E-22 −14.88 2.09E-40 −22.33 2.52E-21 −17.42 1.96E-38 −21.49
ILMN_1780533 RNASE6 1.76E-19 −11.65 6.18E-32 −22.15 1.93E-18 −12.90 8.09E-29 −18.72
ILMN_1728106 TNF 4.94E-19 8.29 9.26E-37 18.69 3.36E-19 10.40 3.89E-33 15.27
Gene expression was determined for each group, and at each time point, between BCG-stimulated and unstimulated peripheral blood mononuclear cells. Changes in
gene expression were determined using linear modeling in limma, including the volunteer as a factor.
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Figure 2. Mycobacteria-speciﬁc whole-blood cytokine responses and the ratio of CD14+ cells to CD3+ T cells in volunteers in study groups A and C on the day of bacillus Calmette-Guerin (BCG) challenge (day
0) and days 2 and 14 after challenge. A–F, Percentages of CD14+ cells, CD4+ T cells, or CD8+ T cells making cytokines. G, Ratio of CD14+ cells to CD3+ T cells in volunteers in the 2 study groups. H, Polyfunctional
CD4+ T-cell cytokine responses. The pie charts illustrates proportions of CD4+ T cells making 1, 2, 3, or 4 cytokines, whereas median percentages of CD4+ T cells making these cytokine are shown in the bar chart.
P values for differences in frequencies of polyfunctional CD4+ T cells between groups A and C at day 14 are shown in the table. Box and whisker plots show median values, interquartile ranges, and minimum and
maximum values. Abbrevations: IFN-γ, interferon γ; IL-2, interleukin 2; IL-17, interleukin 17; PPD, puriﬁed protein derivative; TNF-α, tumor necrosis factor α.
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We determined PPD-speciﬁc cytokine responses in whole-
blood samples collected from volunteers in groups A and C at
days 0, 2, and 14 after BCG challenge (Figure 2A and 2G). Fre-
quencies of CD14+ cells producing TNF-α were comparable at
baseline, indicating preexisting innate immune response to
BCG in the 2 study groups. At day 14, there were more
CD14+ TNF-α–expressing cells in group C, compared with
group A. Study of the lymphocyte cytokine proﬁle in the 2
groups revealed that levels of CD4+ T cells producing IFN-γ
and TNF-α and CD8+ T cells producing IFN-γ were signiﬁ-
cantly higher in group C, compared with group A, at all 3
time points. Additionally, levels of CD4+ T cells producing
IL-2 and IL-17 were signiﬁcantly higher in group C volunteers
at days 0 and 14.
As monocytes are considered an important population of
cells in which mycobacteria reside, while lymphocytes are
known to be the major effector cells in tuberculosis immunity,
we investigated the effect of BCG challenge on the ratio of
monocytes to lymphocytes (deﬁned as the ratio of CD14+
cells to CD3+ T cells in the unstimulated samples). This ratio
was signiﬁcantly higher in group C at days 2 and 14 after chal-
lenge than in group A (Figure 2H). Finally, polyfunctional
CD4+ T cells were detected in both groups, with group C show-
ing signiﬁcantly higher frequencies of CD4+ T cells making
multiple cytokines simultaneously (Figure 2I).
We next correlated cytokine production quantiﬁed by ﬂow
cytometry of PPD-stimulated whole blood with expression of
the same cytokines measured by microarray analysis of BCG-
stimulated PBMCs (Figure 3). The percentage of CD4+ T cells
expressing IL-2, IFN-γ, and IL-17 correlated with the microar-
ray values obtained for these genes (IFN-γ: Pearson r = 0.68,
P = .001; IL-2: Pearson r = 0.68, P = .01; and IL-17: Pearson
r = 0.51, P = .02). By contrast, the values for TNF-α production
did not correlate with either TNF-α–expressing CD4+ T cells or
TNF-α–expressing CD14+ cells (data not shown), perhaps re-
ﬂecting production of TNF by a greater variety of cell types.
BCG Growth Correlates Inversely With Scar Severity and
Cytokine Production
BCG growth was measured by qPCR of the biopsy specimen,
and these data have been previously reported [5]. Photos of
the BCG vaccination site were taken immediately before biopsy,
and these were ranked to give a measure of severity of the local
reaction (termed “scar severity”). The photos were ranked by
Figure 3. Correlation of cytokine expression, measured by gene expression microarray and intracellular cytokine staining. Cytokine production following
bacillus Calmette-Guerin (BCG) stimulation (measured by DNA microarray) or puriﬁed protein derivative stimulation (measured by ﬂow cytometry) were
determined. Pearson correlation analysis was performed between values obtained by DNA microarray and the percentage of cytokine-positive CD4+ T
cells. Abbreviations: IFN-γ, interferon γ; IL-2, interleukin 2; IL-17, interleukin 17; NS, not signiﬁcant; TNF-α, tumor necrosis factor α.
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the trial clinician before determination of the BCG burden in
the biopsy specimen by qPCR. Ranked photos are shown in
Supplementary Figure 1. There was an inverse correlation ob-
served between scar severity and BCG growth (Spearman
ρ = −0.71, P < .001; Figure 4).
Expression of cytokines and related genes, as measured by
both ﬂow cytometry and DNA microarray, were correlated to
BCG growth and scar severity values (Table 3). Figures showing
the correlations of cytokines and selected genes with BCG
growth and scar severity are also shown in Supplementary Fig-
ure 2. The inﬂammatory cytokines IFN-γ, IL-17, IL-2, interleu-
kin 22 (IL-22), interleukin 23 (IL-23), and CXCL3 showed an
inverse correlation with BCG growth and a positive correlation
with scar severity. By contrast, the pattern-recognition receptor
NOD2 and members of the leukocyte immunoglobulin-like re-
ceptor (LILR) family correlated in the opposite direction. Addi-
tionally, in polyfunctional T cells, the production of the
following combinations of cytokines at day 14 showed a corre-
lation with inhibition of BCG growth: IFN-γ, TNF-α, and IL-2
(P = .0007); TNF-α, IL-2, and IL-17 (P = .0127); IFN-γ and
TNF-α (P = .0125); and TNF-α and IL-17 (P = .0091). The re-
sponse to BCG/PPD stimulation changed over the course of the
challenge, with the fewest correlations seen 2 days after BCG,
reﬂecting the evolving immune response.
DISCUSSION
BCG has been administered to >3 billion people since its intro-
duction >90 years ago. During this time, the prevalence of tu-
berculosis has fallen dramatically in some countries, but in
others it is higher than ever. The use of a human BCG challenge
model as a surrogate of protection against which to test novel
vaccines may prove a valuable tool in early selection of promis-
ing vaccine candidates [5, 6]. BCG is known to be highly effec-
tive in the United Kingdom, giving around 80% protection [16].
The aims of the study were to characterize the kinetics of the
immune response to BCG in naive and previously vaccinated
volunteers and to look for correlations between these immune
parameters and the number of mycobacteria recovered from the
site of injection at the end of the challenge period.
The immune response in unstimulated and stimulated cells
in both groups showed activation of innate immunity to BCG.
In the previously vaccinated volunteers, however (group C), the
fold changes were much higher, indicating that prior exposure
to BCG increases the magnitude of the immune response. These
observations are consistent with previous microarray studies
done in naive and BCG-vaccinated mice challenged with BCG
[17]. Although the 2 groups showed a degree of overlap in dif-
ferentially expressed genes, fold changes were much higher in
the vaccinated mice. Additionally, similar pathways were mod-
ulated in both human volunteers and mice. BCG challenge in
previously BCG-vaccinated humans caused the monocyte to
lymphocyte ratio to increase, compared with that in BCG-
naive subjects, which is likely to affect the gene expression mea-
sured by microarray. The signiﬁcance of this change is not clear
and could be caused, for example, by proliferation of monocytes
following BCG vaccination.
The BCG challenge model allows associations to be made be-
tween different immune parameters and BCG growth. In this
trial, previously BCG-vaccinated volunteers had signiﬁcantly
lower amounts of BCG recovered from the challenge site, com-
pared with BCG-naive volunteers, consistent with the protective
effect of BCG in this population. This was therefore a good op-
portunity to identify potential correlates of mycobacterial con-
trol. Genes in which a change in expression in the stimulated as
compared to unstimulated samples was associated with BCG
growth included IFNG and IL17F, together with other genes as-
sociated with these 2 cytokines, such asNOD2, IL22, IL23A, and
FCGR1B. Several recent studies have reported important roles
for these cytokines in protection fromM. tuberculosis infection.
IFN-γ is known to be necessary, although not sufﬁcient, for
protection, and recent studies also suggest an important role
for T-helper type 17 (Th17) cells and the IL-23/IL-17 pathway.
The latter can provide partial protection from M. tuberculosis
challenge and have been shown to be necessary drivers of Th1
immunity and IFN-γ responses in the face of interleukin 10
production during infection [18–20]. In cattle, IL-22 and
Figure 4. Scar severity correlates inversely with mycobacterial growth.
Mycobacterial growth was measured by quantitative polymerase chain re-
action analysis of bacillus Calmette-Guerin (BCG) in biopsy samples ob-
tained from the site of BCG injection 14 days after vaccination. Scar
severity was determined by ranking photos of the vaccination site taken
immediately before biopsy. The ranking of the severity of local reactions
was performed by the trial clinician before quantiﬁcation of BCG in the
biopsy specimens. Group A, open triangles; group C, ﬁlled circles. Spear-
man ρ =−0.71, P < .001.
1506 • JID 2015:211 (1 May) • Matsumiya et al
IFN-γ production by PPD-stimulated PBMCs were identiﬁed
as the primary predictors of vaccine induced protection in
a Mycobacterium bovis challenge model [21]. Additionally, a
recent article identiﬁed NOD2 as a crucial component of epi-
genetic reprogramming of monocytes following BCG vaccina-
tion, which led to nonspeciﬁc protective effects [22]. In this
study, levels of polyfunctional CD4+ T cells were signiﬁcantly
higher in BCG-vaccinated volunteers 2 weeks after BCG chal-
lenge, and cells producing multiple cytokines have previously
been shown to be associated with protection in a Leishmania
major model [23]. Here, we show a negative correlation be-
tween BCG growth and frequencies of CD4+ T cells producing
combined cytokines (IFN-γ, TNF-α, and IL-2; TNF-α, IL-2,
and IL-17; IFN-γ and TNF-α; and TNF-α and IL-17) 14
days after challenge.
In this study, the identiﬁcation of T cells producing IL-2 and
IL-17 in previously BCG-vaccinated volunteers before BCG
challenge may suggest the presence of a pool of central memory
T cells, a response that is then boosted following BCG challenge.
Other studies have previously shown that BCG can induce cen-
tral memory T-cell responses in different populations [24, 25].
Unfortunately, markers to identify memory populations of
T cells were not included in these experiments, and exploring
this would require further testing. It is unlikely that time
since BCG vaccination can explain the data, because we have
not seen a correlation between response to BCG by IFN-γ ELI-
SPOT and time since BCG vaccination in this or any other pre-
vious studies. Finally, although our data show an inverse
correlation between cytokine production and BCG growth, in
a previously published efﬁcacy trial in South African infants, in-
creased cytokine production in response to PPD stimulation in
BCG- and MVA85A-vaccinated infants was not associated with
protection [4]. However, this may be because the magnitude of
the response was much lower in South African infants. Further-
more, differences in age and population make it difﬁcult to draw
parallels between the 2 studies.
The increase in local adverse events following a second BCG
vaccination is well documented and was also seen in this study
[6, 26, 27].The severity of local inﬂammation correlated with the
immune response (IL17F, IFNG, FCGR1B) and increased con-
trol of mycobacterial growth. The balance between bacterial
killing and excessive inﬂammation is at the core of the rela-
tionship between humans and M. tuberculosis. These data
show that too little inﬂammation fails to control mycobacterial
growth, whereas a protective immune response comes at the
cost of collateral damage. BCG has been shown to be effective
Table 3. Correlation Between Cytokine Production and Bacillus Calmette-Guerin (BCG) Growth or Scar Severity
Variable
Day 0 (Challenge), P (r)a Day 2, P (r)a Day 7, P (r)a Day 14 (Biopsy), P (r)a
BCG
Growth Scar BCG Growth Scar BCG Growth Scar
BCG
Growth Scar
Flow cytometry
CD4+ IFN-γ+ NS NS NS .0102 (0.5737) ND ND <.0001 (−0.7754) .002 (0.6614)
CD4+ TNF-α+ NS NS NS .0139 (0.5538) ND ND <.0001 (−0.7675) .0017 (0.6702)
CD4+ IL-2+ NS NS NS .0073 (0.5940) ND ND <.0001 (−0.7860) .001 (0.6924)
CD4+ IL-17+ NS NS NS NS ND ND .0063 (−0.552) NS
CD8+ IFN-γ+ NS NS NS NS ND ND <.0001 (−0.7233) .0013 (0.6819)
Gene expression
CXCL3 .003 (−0.6) .018 (0.5) NS NS NS NS NS NS
NOD2 .001 (0.6) NS NS NS NS NS .024 (0.5) NS
FCGR1B .03 (0.5) NS NS NS NS NS .01 (0.6) NS
IL10RB .0003 (0.7) .035 (−0.5) NS NS NS .045 (−0.4) NS NS
IL17F .011 (−0.5) .006 (0.6) NS NS .002 (−0.7) .017 (0.6) <.0001 (−0.8) .006 (0.7)
F3 .04 (−0.4) NS .015 (−0.5) NS NS NS .031 (−0.5) NS
FAS .018 (−0.5) .018 (0.5) NS NS .026 (−0.5) .013 (0.6) NS .044 (0.5)
LILR A5/A6/B2 .01 (0.5) .02 (−0.5) NS NS .01 (0.5) .02 (−0.5) .01 (0.6) .02 (−0.5)
IL5 NS .029 (0.5) NS NS .014 (−0.5) .024 (0.5) .005 (−0.6) .003 (0.7)
IFNG NS .02 (0.5) NS NS .003 (−0.6) .014 (0.6) .031 (−0.5) NS
IL2 NS NS .011 (−0.6) .016 (0.6) .024 (−0.5) .027 (0.5) .003 (−0.6) NS
Cytokine production was measured in peripheral blood mononuclear cells stimulated by purified protein derivative/BCG, with the background value (unstimulated)
subtracted. BCG growth and scar severity were determined 14 days after challenge.
Abbreviations: BCG, Bacillus Calmette-Guerin; IFN-γ, interferon γ; IL-2, interleukin 2; IL-17, interleukin 17; LILR, lymphocyte immunoglobulin-like receptor; ND, assay
not done; NS, not significant; TNF-α, tumor necrosis factor α.
a P values are not corrected, and all correlations are Spearman r. Correlations were performed for all 24 volunteers, separately for each day.
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in protecting the United Kingdom population from tuberculo-
sis, suggesting that the spectrum seen here in group C may in-
dicate an optimal balance. In Malawi, where BCG is not
protective, vaccinated infants develop smaller scars, weaker
Th1 responses, and stronger Th2 and regulatory responses in
response to PPD-T stimulation, compared with their United
Kingdom counterparts [28]. Likewise, laboratory mice in Brazil
and Mexico show less susceptibility to infection with M. tuber-
culosis and also less protection from BCG [29]. Although the
data shown here and recent studies suggest a role for the IL-
17 pathway in the development of a protective response, exces-
sive activation of this pathway has also been associated with
detrimental tissue damage in this and other diseases [18, 30, 31],
and the level of this cytokine’s importance in vaccine-induced
immunity is presently unknown. The human BCG challenge
model may become a powerful tool in future vaccine research,
both in terms of vaccine evaluation and for the identiﬁcation of
potential immune correlates of protection. An important next
step will be to test this model and characterize the response to
BCG in populations where BCG is not effective, which may
yield insight as to why these differences exist and how they re-
late to control of mycobacterial growth.
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